These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24142143)

  • 1. Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.
    Greenough A
    Evid Based Med; 2014 Apr; 19(2):65. PubMed ID: 24142143
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory syncytial virus and recurrent wheeze.
    Blanken MO; Rovers MM; Bont L;
    N Engl J Med; 2013 Aug; 369(8):782-3. PubMed ID: 23964947
    [No Abstract]   [Full Text] [Related]  

  • 4. Respiratory syncytial virus and recurrent wheeze.
    Brand PL
    N Engl J Med; 2013 Aug; 369(8):782. PubMed ID: 23964948
    [No Abstract]   [Full Text] [Related]  

  • 5. Early-life wheezing and respiratory syncytial virus prevention.
    Lemanske RF
    N Engl J Med; 2013 May; 368(19):1839-41. PubMed ID: 23656652
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    McLaurin K; Ambrose CS
    Pediatrics; 2014 Apr; 133(4):e1101. PubMed ID: 24692037
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection.
    Lanari M; Vandini S; Arcuri S; Galletti S; Faldella G
    Clin Dev Immunol; 2013; 2013():359683. PubMed ID: 23840240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    Meissner HC; Kimberlin DW
    Pediatrics; 2014 Apr; 133(4):e1101-3. PubMed ID: 24692038
    [No Abstract]   [Full Text] [Related]  

  • 11. RSV immunoprophylaxis: does the benefit justify the cost?
    Meissner HC; Kimberlin DW
    Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
    [No Abstract]   [Full Text] [Related]  

  • 12. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis against respiratory syncytial virus in premature infants.
    Björklund LJ; Lindroth M; Polberger S; Selander B
    Lancet; 2000 Jan; 355(9199):235-6. PubMed ID: 10675148
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?
    Moraes T
    Can Respir J; 2014; 21(3):163-4. PubMed ID: 24914608
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylaxis for respiratory syncytial virus bronchiolitis.
    Nadal D; Berger C; Aebi C; Kind C
    Lancet; 1999 Dec; 354(9194):1997. PubMed ID: 10622321
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.
    Paes B; Lanctôt K
    Turk J Pediatr; 2013; 55(5):564-7. PubMed ID: 24382545
    [No Abstract]   [Full Text] [Related]  

  • 19. Palivizumab and emerging therapies for respiratory syncytial virus.
    Hoopes JM; Makari D; Groothuis J
    Expert Opin Biol Ther; 2012 May; 12(5):547-8; author reply 549. PubMed ID: 22348302
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
    Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; Grantina I; Nguyen KA; Brooks D; Chang Y; Leach A; Takas T; Yuan Y; Griffin MP; Mankad VS; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):892-894. PubMed ID: 35235733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.